Active Procollagen II N-Terminal Propeptide (PIINP)

Catalog#:PHH12305

概述（Summary）

别称（Alternative Names）	P2NP; N-Propeptide Of Type II Procollagen; Procollagen II Amino Terminal Propeptide
纯度（Purity）	Greater than 95% as determined by reducing SDS-PAGE.
内毒素（Endotoxin level）	Please contact with the lab for this information
蛋白构建（Construction）	【Gln26-Ala181】
Accession #	P02458
表达宿主（Host）	293F
种属（Species）	Homo sapiens (Human)
预测分子量（Predicted MW）	17.3 kDa
制剂（Form）	Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
运输方式（Shipping）	The product is shipped with ice bag. Upon receipt, store it immediately at the temperature listed below.
稳定性&储存（Stability &Storage）	12 months at -20°C to -80°C in lyophilized state.6 months at -20°C to -80°C under sterile conditions after reconstitution.7-10 days at 2°C to 8°C under sterile conditions after reconstitution.Please minimize freeze-thaw cycles.
复溶（Reconstitution）	Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
背景介绍（References）	Type II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces.

电泳图（SDS-PAGE image）



Greater than 95% as determined by reducing SDS-PAGE.

活性图（Bioactivity image）



Figure 1. The binding activity of PIINP with ITGb1

Procollagen II N-Terminal Propeptide is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces, which was are associated with achondrogenesis, chondrodysplasia, early onset familial osteoarthritis, Langer-Saldino achondrogenesis, SED congenita, Kniest dysplasia, Stickler syndrome type I, and spondyloepimetaphyseal dysplasia Strudwick type. A binding ELISA assay was conducted to detect the association of PIINP with ITGb1. Briefly, ITGb1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 ul ITGb1 were then transferred to PIINP-coated microtiter wells (2ug/ml, 100ul/well) and incubated for 1h at 37 ℃. Wells were washed with PBST and incubated for 1h with anti-ITGb1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 uL stop solution to the wells and read at 450nm immediately. The binding activity of PIINP with ITGb1 was shown in Figure 1, and this effect was in a dose dependent manner, the EC50 was approximately 2.82 ug/mL.

注意事项（Note）

For Research Use Only , Not for Diagnostic Use.